BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic solutions for individuals grappling with severe and life-threatening rare diseases. Its array of market-ready products features Vimizim, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A; Naglazyme, a recombinant N-acetylgalactosamine 4-sulfatase addressing MPS VI; and Kuvan, a proprietary oral synthetic 6R-BH4 compound used to manage phenylketonuria (PKU), an inherited metabolic disorder. The commercial portfolio also includes Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme delivered via subcutaneous injection to lower blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for ceroid lipofuscinosis type 2 (a form of Batten disease); Voxzogo, a daily injectable c-type natriuretic peptide analog for achondroplasia; and Aldurazyme, a purified protein mirroring the natural human enzyme alpha-L-iduronidase.